Hubei Biocause Pharmaceutical Balance Sheet Health
Financial Health criteria checks 2/6
Hubei Biocause Pharmaceutical has a total shareholder equity of CN¥36.0B and total debt of CN¥17.5B, which brings its debt-to-equity ratio to 48.6%. Its total assets and total liabilities are CN¥285.2B and CN¥249.1B respectively.
Key information
48.6%
Debt to equity ratio
CN¥17.49b
Debt
| Interest coverage ratio | n/a |
| Cash | CN¥10.77b |
| Equity | CN¥36.00b |
| Total liabilities | CN¥249.15b |
| Total assets | CN¥285.15b |
Recent financial health updates
No updates
Recent updates
Further Upside For Hubei Biocause Pharmaceutical Co., Ltd. (SZSE:000627) Shares Could Introduce Price Risks After 29% Bounce
Dec 16
Hubei Biocause Pharmaceutical Co., Ltd.'s (SZSE:000627) Shares Leap 43% Yet They're Still Not Telling The Full Story
Oct 23Further Upside For Hubei Biocause Pharmaceutical Co., Ltd. (SZSE:000627) Shares Could Introduce Price Risks After 32% Bounce
Sep 05Improved Revenues Required Before Hubei Biocause Pharmaceutical Co., Ltd. (SZSE:000627) Shares Find Their Feet
Jun 10Fewer Investors Than Expected Jumping On Hubei Biocause Pharmaceutical Co., Ltd. (SZSE:000627)
Mar 05Financial Position Analysis
Short Term Liabilities: 000627's short term assets (CN¥33.9B) exceed its short term liabilities (CN¥17.4B).
Long Term Liabilities: 000627's short term assets (CN¥33.9B) do not cover its long term liabilities (CN¥231.7B).
Debt to Equity History and Analysis
Debt Level: 000627's net debt to equity ratio (18.6%) is considered satisfactory.
Reducing Debt: 000627's debt to equity ratio has increased from 10% to 48.6% over the past 5 years.
Debt Coverage: 000627's operating cash flow is negative, therefore debt is not well covered.
Interest Coverage: Insufficient data to determine if 000627's interest payments on its debt are well covered by EBIT.
Balance Sheet
Discover healthy companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/25 07:47 |
| End of Day Share Price | 2024/12/25 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Hubei Biocause Pharmaceutical Co., Ltd. is covered by 2 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Jun Liu | Changjiang Securities Co. LTD. |
| Yeyong Meng | SWS Research Co., Ltd. |